Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Conditions
Non-Hodgkin Lymphoma · B-cell Acute Lymphoblastic Leukemia · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
City of Hope, Duarte, California, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Contact: Study coordinator (Clinical Research)Contact: Principal Investigator (Bijal Shah, MD)Winship Cancer Institute Emory University, Atlanta, Georgia, United States
Contact: Study coordinator (Clinical Trials)Contact: Principal Investigator (Edmund Waller, MD)Northside Hospital Cancer Institute, Atlanta, Georgia, United States
Contact: Study coordinator (Clinical Trials)Contact: Principal Investigator (Scott Solomon, MD)University of Maryland, Baltimore, Maryland, United States
Contact: Study coordinator (Clinical Trials)Contact: Principal Investigator (Jean Yared, MD)Tufts Medical Center, Boston, Massachusetts, United States
Contact: Study coordinator (Clinical Trials)Contact: Principal Investigator (Andreas Klein, MD)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute (Wayne State University), Detroit, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
Contact: Study coordinator (Clinical Research)Contact: Principal Investigator (Supriya Gupta, MD)Weill Cornell Medical College - NY Presbyterian Hospital, New York, New York, United States
Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, New York, United States
Contact: Study coordinator (Clinical Trials)Contact: Principal Investigator (Ran Reshef, MD)Duke University, Durham, North Carolina, United States
Ohio State University, Columbus, Ohio, United States
Lifespan Cancer Institute at Rhode Island Hospital, Providence, Rhode Island, United States
Contact: Study coordinator (Clinical Trials)Contact: Principal Investigator (Adam Olszewski, MD)Baylor University Medical Center, Dallas, Texas, United States
Contact: Study coordinator (Clinical Trials)Contact: Principal Investigator (Houston Holmes III, MD)MD Anderson, Houston, Texas, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact: Study coordinator (Clinical Trials)Contact: Principal Investigator (Nirav Shah, MD)Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Contact: Study coordinator (Dr Vinay Vanguru)Liverpool Hospital, Liverpool, New South Wales, Australia
Contact: Study coordinator (Dr Nagendra P Sungala)Royal Adelaide Hospital, Adelaide, South Australia, Australia
Contact: Study coordinator (Dr Danielle Blunt)St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Contact: Principal Investigator (Matthew Ku)Barwon Health - Andrew Love Cancer Centre, Geelong, Victoria, Australia
Contact: Principal Investigator (Hannah Rose)
Study leads
John Byon, MD, PhD
Study Chair
Imugene Limited